Inhaled corticosteroids and leukotriene receptor antagonists induce protection against adenosine 5‘monophosphate induced bronchospasm in a synergic fashion Source: Annual Congress 2007 - Current issues in airway physiology, pharmacology and monitoring Year: 2007
Anti-inflammatory effects of histamine H1 -receptor antagonist and leukotriene CysLT1 -receptor antagonist in patients with atopic asthma maintained on inhaled corticosteroids Source: Eur Respir J 2004; 24: Suppl. 48, 221s Year: 2004
Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma? Source: Eur Respir Rev 2015; 25: 54-64 Year: 2016
Rapid oral desensitization to anti-tuberculosis drugs Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010
Safety and efficacy of P2X3 antagonist BAY 1902607 in refractory chronic cough Source: Virtual Congress 2020 – Chronic cough: only symptom or disease? Year: 2020
Efficacy and safety of Long-acting Beta-agonists+Long-acting muscarinic antagonists vs Long-acting Beta-agonists+Inhaled corticosteroids in COPD: a meta-analysis Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD Year: 2017
Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors and beyond Source: Eur Respir J, 56 (2) 2001610; 10.1183/13993003.01610-2020 Year: 2020
Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists Source: Eur Respir Monogr 2020; 88: 238-250 Year: 2020
Study of improvement of exercise-indused bronchospasm by montelukast, a leukotriene antagonist Source: Eur Respir J 2004; 24: Suppl. 48, 502s Year: 2004
Effects of hydrocortisone on acute beta-blocker and histamine induced bronchoconstriction Source: Annual Congress 2011 - Asthma management and response Year: 2011
LATE-BREAKING ABSTRACT: Inhibition of ATP-gated P2X3 channels by AF-219: An effective anti-tussive mechanism in chronic cough Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013
Safety and efficacy of the inhaled pan-selectin antagonist bimosiamose in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 613s Year: 2007
The efficacy and safety of long-acting muscarinic antagonist treatment for COPD Source: International Congress 2019 – Advances in chronic obstructive pulmonary disease and asthma Year: 2019
Long-term treatment with a leukotriene antagonist Source: Eur Respir J 2004; 24: Suppl. 48, 126s Year: 2004
Emergency treatment of asthma attacks with nebulized beta-2-adrenergic agonist Source: Eur Respir J 2001; 18: Suppl. 33, 235s Year: 2001
In vivo potent and long-lasting bronchodilator activity of muscarinic M3 receptor antagonist CHF5407Source: Eur Respir J 2007; 30: Suppl. 51, 26s Year: 2007
Is there a problem with short-acting beta-2 agonist monotherapy in asthma? Source: Virtual Congress 2020 – Airway diseases Year: 2020
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Airway responsiveness to beta-adrenergic agonist in smokers Source: Eur Respir J 2004; 24: Suppl. 48, 341s Year: 2004
Sustained efficacy with the selective endothelin-A receptor antagonist, sitaxsentan, after two years of therapy in patients with pulmonary arterial hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 204s Year: 2005